Nextcure to give two presentations at society for immunotherapy of cancer annual meeting

Beltsville, md., oct. 04, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the society for immunotherapy of cancer (sitc) annual meeting, to be held in houston, tx from november 6-10, 2024. nextcure will share pre-clinical data from lncb74 (b7-h4 adc) and biomarker data from nc410 combination study with pembrolizumab in ici-naÏve mss/msi-l crc during poster sessions.
NXTC Ratings Summary
NXTC Quant Ranking